Björn Bornkamp (Novartis), David Ohlssen(Novartis), Mark Rothmann (FDA), Chenguang Wang and Dong Xi (Gilead)
Share this post
2024 ASA Biopharmaceutical Section…
Share this post
Björn Bornkamp (Novartis), David Ohlssen(Novartis), Mark Rothmann (FDA), Chenguang Wang and Dong Xi (Gilead)